ADMA Biologics Inc vs Robinhood Markets, Inc. — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while Robinhood Markets, Inc. trades at $93.66 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 38.2× ADMA Biologics Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | HOOD | |
|---|---|---|
Market Cap | $2.22B | $84.86B |
Sector | Health | Technology |
52-Week High | $20.38 | $152.46 |
52-Week Low | $7.60 | $65.16 |
Enterprise Value | $2.29B | $91.40B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Robinhood (HOOD) trades at $94.52, up 1.32% in 24 hours, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.62 actual vs. $0.44 expected, and revenue growth of 32% year-over-year. Recent news highlights expansion into UK crypto services and product diversification, though technical indicators suggest caution amid high valuation multiples.
Outlook: Bullish fundamentals with robust revenue growth and profit margins, but elevated P/E of 41.76 poses valuation risk. Opportunities include international expansion and non-crypto revenue streams; risks involve competitive pressures and reliance on market volatility. Analyst consensus price target of $123.46 implies significant upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →